The Cancer Letter

Inside information on cancer research and drug development

Drugs & Targets

Foundation Medicine to develop companion diagnostics for Lilly’s Retevmo and Loxo Oncology at Lilly’s pipeline

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Foundation Medicine Inc. and Eli Lilly and Company entered a collaboration for the development of Foundation Medicine’s tissue- and blood-based assays as companion diagnostics for Retevmo (selpercatinib) and other therapies in Loxo Oncology at Lilly’s pipeline. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Drugs & Targets

Veeva and Merck form long-term strategic partnership

Veeva Systems formed a ten-year strategic partnership agreement with Merck, that builds on the existing 12-year partnership between the companies. Under the terms of the agreement, Merck will take a Veeva-first approach to new industry-specific software and data, selecting Veeva products when they are fit for purpose to maximize the value of Veeva’s integrated, cloud-based platform and products. 
Table of Contents

Login

Site license subscribers:
Log in with your IP | Register a sponsored account